Results 161 to 170 of about 63,782 (312)

Hapten-Based Cancer Immunotherapy: From Immune Activation to Antitumor Activity. [PDF]

Cells
Richert I, Chalus L, Pinteur B, Bravetti P, Tortorelli C, Alzeeb G, Ghiringhelli F.   +6 more
europepmc   +1 more source

Current Cell/Organoid and Animal Models for Primary Sclerosing Cholangitis

Portal Hypertension &Cirrhosis, EarlyView.
Primary sclerosing cholangitis (PSC) is a chronic cholestatic liver disease with limited therapeutic options and a marked risk of progression to biliary fibrosis, cirrhosis, and malignancy. Progress in PSC research has been hindered by the lack of models that faithfully recapitulate the complex biliary microenvironment and disease heterogeneity ...
Qigu Yao, Sheng Cheng, Qiaoling Pan, Jiong Yu, Hongcui Cao   +4 more
wiley   +1 more source

HLA Class I Loss and Resistance to Immunotherapy in Pulmonary Metastasis of Hypopharyngeal Cancer. [PDF]

In Vivo
Murakami A, Yukino K, Komohara Y, Shimoda YU, Saito H, Fujiwara Y, Orita Y.   +6 more
europepmc   +1 more source

Integrative Modeling in the Age of Machine Learning: A Summary of HADDOCK Strategies in CAPRI Rounds 47–55

Proteins: Structure, Function, and Bioinformatics, EarlyView.
ABSTRACT The HADDOCK team participated in CAPRI rounds 47–55 as server, manual predictor, and scorers. Throughout these CAPRI rounds, we used a plethora of computational strategies to predict the structure of protein complexes. Of the 10 targets comprising 24 interfaces, we achieved acceptable or better models for 3 targets in the human category and 1 ...
Victor Reys, Marco Giulini, Vlad Cojocaru, Anna Engel, Xiaotong Xu, Jorge Roel‐Touris, Cunliang Geng, Francesco Ambrosetti, Brian Jiménez‐García, Zuzana Jandova, Panagiotis I. Koukos, Charlotte van Noort, João M. C. Teixeira, Siri C. van Keulen, Manon Réau, Rodrigo V. Honorato, Alexandre M. J. J. Bonvin   +16 more
wiley   +1 more source

Correlation between recognition of autologous tumor organoids by tumor-infiltrating lymphocytes from metastatic epithelial cancers and clinical response. [PDF]

J Immunother Cancer
Gustafson AM, Bhasin A, Gasmi B, Bui BD, Ade CM, Hanada KI, Halas HK, Gartner JJ, Prickett TD, Salazar J, Parkhust MR, Robbins P, Klemen ND, Kwong ML, Goff SL, Rosenberg SA, Yang JC.   +16 more
europepmc   +1 more source

Massive Sampling Strategy for Antibody–Antigen Targets in CAPRI Round 55 With MassiveFold

Proteins: Structure, Function, and Bioinformatics, EarlyView.
ABSTRACT Massive sampling with AlphaFold2 improves protein–protein complex predictions. This has been shown during the last CASP15‐CAPRI blind prediction round by the AFsample tool. However, more difficult targets including antibody–antigen binding remain challenging. CAPRI Round 55 consisted of three antibody–antigen targets and one heterotrimer.
Nessim Raouraoua, Marc F. Lensink, Guillaume Brysbaert   +2 more
wiley   +1 more source

A Platform for High-throughput and Ultrasensitive Immunopeptidomics. [PDF]

Mol Cell Proteomics
Gul A, Van Moortel L, Willems P, Aernout I, Pedró-Cos L, Ferrell KC, Boucher K, Staes A, Devos S, Lentacker I, Vandekerckhove B, Demangel C, Thery F, Impens F.   +13 more
europepmc   +1 more source

Biomolecular Interaction Prediction in the Pre‐ and Post‐AlphaFold Era: The 8th CAPRI Evaluation

Proteins: Structure, Function, and Bioinformatics, EarlyView.
ABSTRACT We report on the 8th CAPRI Evaluation period, capturing the assessment of CAPRI Rounds 47 to 55 (excluding the CASP and COVID‐related Rounds), which have witnessed the transition to AI‐driven prediction tools such as AlphaFold and related alternatives. The prediction Rounds in this evaluation are characterized by a high level of difficulty due
Marc F. Lensink, Nessim Raouraoua, Guillaume Brysbaert, Sameer Velankar, Shoshana J. Wodak, Alexandre M. J. J. Bonvin   +5 more
wiley   +1 more source

The use of fusion proteins to study HLA-B27-specific allorecognition [PDF]

, 1989
Wildner, G., Szöts, Hannelore, Schendel, Dolores J., Weiss, Elisabeth H., Riethmüller, Gert   +4 more
core   +1 more source

Nanoparticle-mediated dual delivery of MHC class I and II antigens enhances T cell immunity and anti-tumor potency. [PDF]

Biomaterials
Li E, Butkovich N, Tucker JA, Nelson EL, Wang SW.   +4 more
europepmc   +1 more source